Summit Therapeutics announced cash bonuses of $540,000 each for CEO Mahkam Zanganeh and CFO Manmeet Soni for 2024, with payments scheduled for early 2025. Their annual base salaries will increase to $618,000 starting February 1, 2025. The company reported preliminary unaudited cash, cash equivalents, and short-term investments of $412 million as of December 31, 2024, which includes the repayment of a $31.8 million related party loan. Final figures are pending completion of financial procedures.